In vivo study for the hemostatic efficacy and foreign body reaction of a new powder-type polysaccharide hemostatic agent

다국어 초록 (Multilingual Abstract)

Purpose: Various hemostatic agents have been introduced in therapy as postoperative bleeding is a poor prognostic factor for postoperative outcomes. These products can be divided into those that directly promote the hemostatic cascade and those that physically form a barrier by absorbing blood. The latter, powder-type hemostatic agents have the advantages of being inexpensive and more absorbable with less foreign body reactions (FBRs) and are applicable to a relatively wide area.
This study was conducted to verify the safety and efficacy of a newly invented polysaccharide product (OOZFIX, Theracion Biomedical), which improves blood absorption and hemostatic effects.
Methods: Two separate animal experiments were performed. The first evaluated FBRs histologically at 3 days, 2 weeks, and 4 weeks, after implantation of OOZFIX in rats, and the second compared hemostatic performance of OOZFIX and Arista AH (Bard) in the porcine liver punch biopsy model.
Results: We found minimal FBRs in the 3-day group and no reactions in both the 2-week and 4-week groups after implantation of hemostatic agents. The time to hemostasis of OOZFIX was not significantly different from that of Arista AH (median [interquartile range]: 9 [6–10] minutes vs. 8 [6–10] minutes, respectively; P = 0.522). When comparing the serial bleeding grade tendency, there was no statistical difference between OOZFIX and Arista AH (P = 0.656).
Conclusion: OOZFIX caused a minimal FBR that disappeared within 2 weeks in vivo, and its hemostatic performance was comparable with that of an existing agent, Arista AH. Further clinical studies are required in the future.

참고문헌 (Reference)

1 Boonstra EA, "Topical haemostatic agents in liver surgery: do we need them?" 11 : 306-310, 2009

2 Seyednejad H, "Topical haemostatic agents" 95 : 1197-1225, 2008

3 Shah A, "Strategies to minimize intraoperative blood loss during major surgery" 107 : e26-e38, 2020

4 Hachem LD, "Postoperative surgical-site hemorrhage after kidney transplantation : incidence, risk factors, and outcomes" 30 : 474-483, 2017

5 Schrem H, "Post-operative hemorrhage after liver transplantation : risk factors and long-term outcome" 21 : 46-e55, 2016

6 Montán C, "Perioperative haemorrhage in endovascular abdominal aneurysm repair affects outcome" 46 : 87-92, 2013

7 Franceschini G, "Internal surgical use of biodegradable carbohydrate polymers. Warning for a conscious and proper use of oxidized regenerated cellulose" 216 : 213-216, 2019

8 Singh RK, "Hemostatic comparison of a polysaccharide powder and a gelatin powder" 32 : 393-401, 2019

9 Antisdel JL, "Hemostat ic agent microporous polysaccharide hemospheres(MPH)does not affect healing or intact sinus mucosa" 118 : 1265-1269, 2008

10 Rosselli DD, "Efficacy of a topical bovine-derived thrombin solution as a hemostatic agent in a rodent model of hepatic injury" 79 : 303-308, 2015

11 Lewis KM, "Development and validation of an intraoperative bleeding severity scale for use in clinical studies of hemostatic agents" 161 : 771-781, 2017

12 Lewis KM, "Comparison of two gelatin and thrombin combination hemostats in a porcine liver abrasion model" 26 : 141-148, 2013

13 Ereth MH, "Comparative safety and efficacy of topical hemostatic agents in a rat neurosurgical model" 63 (63): 369-372, 2008

14 Yang YL, "Common bile duct injury by fibrin glue : report of a rare complication" 21 : 2854-2857, 2015

15 Brustia R, "An update on topical haemostatic agents in liver surgery : systematic review and meta analysis" 23 : 609-621, 2016

16 MacDonald MH, "An in vivo comparison of the efficacy of hemostatic powders, using two porcine bleeding models" 10 : 273-279, 2017